DiaSorin shares hit over 8-yr lows on Q3 miss, guidance cut

DiaSorin SpA

06/11/2025 09:29

** Shares in DiaSorin DIAS.MI slump around 16% to their lowest price since April 2017 after the Italian medical diagnostics group posted Q3 miss and cut its 2025 guidance

** Quarterly adjusted EBITDA decreased 7% to 88 million euros ($102.63 million), below consensus estimate of 98.7 million, as cited by Equita

** Revenues of 280 million euros were below an estimate of 291.3 million

** The company now sees 2025 ex-COVID revenue growth at about 5% (vs +8% before) and adjusted EBITDA margin at around 33% (vs about 34% before)

** Equita notes the results were "weak for all divisions"

** A Milan-based trader says results were disappointing, and the stock is under pressure following the guidance cut

($1 = 0.8575 euros)

 (Reporting by Laura Contemori, Giancarlo Navach)

 ((Laura.contemori@thomsonreuters.com))